Piper Jaffray Companies reiterated their overweight rating on shares of Tetraphase Pharmaceuticals (NASDAQ:TTPH) in a research report sent to investors on Wednesday, The Fly reports. The brokerage currently has a $8.00 target price on the biopharmaceutical company’s stock.
Several other research firms have also commented on TTPH. Zacks Investment Research raised Tetraphase Pharmaceuticals from a sell rating to a hold rating in a report on Friday, January 12th. HC Wainwright raised their price objective on Tetraphase Pharmaceuticals from $15.00 to $17.00 and gave the stock a buy rating in a report on Monday, November 6th. ValuEngine lowered Tetraphase Pharmaceuticals from a sell rating to a strong sell rating in a report on Friday, December 1st. BidaskClub lowered Tetraphase Pharmaceuticals from a hold rating to a sell rating in a report on Friday, February 2nd. Finally, B. Riley initiated coverage on Tetraphase Pharmaceuticals in a report on Monday, February 12th. They set a buy rating and a $11.00 price objective on the stock. Two equities research analysts have rated the stock with a sell rating, three have assigned a hold rating and five have assigned a buy rating to the company’s stock. Tetraphase Pharmaceuticals has a consensus rating of Hold and a consensus target price of $10.39.
Tetraphase Pharmaceuticals (TTPH) opened at $2.12 on Wednesday. The company has a market capitalization of $113.51, a price-to-earnings ratio of -0.74 and a beta of 2.29. Tetraphase Pharmaceuticals has a twelve month low of $2.10 and a twelve month high of $9.93.
Several hedge funds have recently modified their holdings of TTPH. SG Americas Securities LLC acquired a new stake in shares of Tetraphase Pharmaceuticals during the third quarter worth about $107,000. Brighton Jones LLC acquired a new stake in shares of Tetraphase Pharmaceuticals during the third quarter worth about $108,000. Voya Investment Management LLC boosted its stake in shares of Tetraphase Pharmaceuticals by 17.8% during the second quarter. Voya Investment Management LLC now owns 20,583 shares of the biopharmaceutical company’s stock worth $147,000 after buying an additional 3,104 shares during the period. Virtu KCG Holdings LLC acquired a new stake in shares of Tetraphase Pharmaceuticals during the second quarter worth about $147,000. Finally, Ameriprise Financial Inc. acquired a new stake in shares of Tetraphase Pharmaceuticals during the second quarter worth about $162,000. 58.28% of the stock is currently owned by institutional investors.
TRADEMARK VIOLATION WARNING: This report was originally reported by Community Financial News and is owned by of Community Financial News. If you are accessing this report on another website, it was copied illegally and republished in violation of United States & international trademark & copyright legislation. The original version of this report can be viewed at https://www.com-unik.info/2018/02/18/tetraphase-pharmaceuticals-ttph-overweight-rating-reaffirmed-at-piper-jaffray-companies.html.
About Tetraphase Pharmaceuticals
Tetraphase Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant gram-negative infections.
Receive News & Ratings for Tetraphase Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.